[kc_row use_container=”yes” force=”no” column_align=”middle” video_mute=”no” _id=”573″][kc_column width=”12/12″ video_mute=”no” _id=”758315″][kc_column_text _id=”234924″]
A human monoclonal antibody blocking SARS-CoV-2 infection_32366817.pdf
A novel treatment approach to the novel coronavirus an argument for the use of therapeutic plasma exchange for fulminant COVID-1932241301.pdf
A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)_32029004.pdf
A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential DrugRepurposing.pdf
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19_32187464.pdf
A Trial of Lopinavir–Ritonavir in Covid-19_32369281.pdf
ACE2 the Janus-faced protein – from cardiovascular protection to severe acute respiratory syndrome-coronavirus and COVID-19.pdf
Anticoagulant treatment is associated with decreased mortality_32220112.pdf
Assessment of Evidence for COVID-19-Related Treatments: Updated 3/27/2020_ASHP.pdf
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses_28659436 .pdf
Can Antimalarials for COVID-19_Ministry Health Singapure.pdf
Cascada del complemento en pacientes con COVID-19_SEI.pdf
Caution Needed on the Use of Chloroquine and Hydroxychloroquine for Coronavirus Disease 2019_32330276.pdf
Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic_32298807.pdf
Chloroquine and Hydroxychloroquine in the Era of SARS–CoV2-Caution on Their Cardiac Toxicity_32285489 .pdf
Chloroquine_and_hydroxychloroquine_with_or_without_azithromycin_for_COVID-19.pdf
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China a retrospective cohort study_2171076.pdf
Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury_32043983.pdf
Cloroquina e hidroxicloroquina como potenciales terapias frente al COVID-19_SNS.pdf
Collecting and evaluating convalescent plasma for COVID‐19 treatment why and how_32240545.pdf
Compassionate Use of Remdesivir for Patients with Severe Covid-19_32275812.pdf.pdf
Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus-32152082.pdf
Convalescent plasma as a potential therapy for COVID-19_32113510 .pdf
Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options_32284951 .pdf
Covid-19 ibuprofen should not be used for managing symptoms, say doctors and scientists.pdf
COVID-19 infection the perspectives on immune responses.pdf
COVID-19 rapid evidence summary. Acute use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19.pdf
Covid-19 what treatments are being investigated.pdf
Covid-19 — The Search for Effective Therapy32187463.pdf
COVID-19, cytokines and immunosuppression..pdf
COVID-19-registered-trials—an-analysis-1.pdf
COVID-19: consider cytokine storm syndromes and immunosuppression_32192578.pdf
Covid-Remdesivir-CADTH HEALTH TECHNOLOGY REVIEW.pdf
Covid19 rapid guideline_antibiotics for pneumonia in adults in hospital-Guia NICE.pdf
Covid_Swallowing_Web_2020_Mar27.pdf
Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses_32258351.pdf
Cytokine Storm in COVID-19 and Treatment – 32283152.pdf
Desempeño clínico de las pruebas diagnósticas de laboratorio en la infección por SARS-CoV-2_Universidad de Antioquia.pdf
Early, low-dose and short-term application of corticosteroid treatment in patients with severo COVID-19 pneumonia-single center experience from Wuham.pdf
Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection-32330277.pdf
Effectiveness and safety of antiviral or antibody treatments for coronavirus_CEBM.pdf
Effectiveness of convalescent plasma therapy in severe COVID-19 patients_ 32253318.pdf
Effectiveness of glucocorticoid therapy in patients with severe novel coronavirus pneumonia protocol of a randomized controlled trial_32149773.pdf
Efficacy and safety of lopinavir ritonavir or arbidol in adult patients with mild moderate COVID-19. An exploratory randomized controlled trial_Pre-proof.pdf
Estimated population wide benefits and risks in China of lowering sodium through potassium enriched salt substitution_modelling study-32321724.pdf
Evaluating the drug-drug interaction risk of experimental COVID-19 therapies.pdf
Evidencia disponible de los fármacos utilizados en pacientes con COVID-19 (I). Corticoides sistémicos_SaludCastillayLeon.pdf
Evidencia disponible de los fármacos utilizados en pacientes con COVID-19 (II) Hidroxicloroquina y azitromicina_SaludCastillayLeon.pdf
Experimental Treatment with Favipiravir for COVID-19. An Open-Label Control Study_ 32346491.pdf
Guidance on the use of biologic agents during COVID-19 outbreak_AAD.pdf
Guiding Principles from American College of Rheumatology for Scarce Resource Allocation During COVID-19 Pandemic. The case of Hydroxychloroquine.pdf
Handbook of COVID-19 Prevention and Treatment.pdf
How to Reduce the Likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) Infection and Lung Inflammation Mediated by IL-1-32228825.pdf
Hydroxychloroquine and Azithromycin as a Treatment of COVID-19- Results of an Open-Label Non-Randomized Clinical Trial-32205204.pdf
Hydroxychloroquine Versus COVID-19: A Rapid Systematic Review and Meta-Analysis
Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia_32196410.pdf
Immune Responses to Middle East Respiratory Syndrome Coronavirus During the Acute and Convalescent Phases of Human Infection_30060038 .pdf
Immunosuppression for Hyperinflammation in COVID-19- A Double-Edged Sword?_32220278.pdf
Infectious diseases society of america guidelines on the treatmen and management of patients with covid-19.pdf
Interacciones_Fármacos_COVID19_HUValme.jpg
Interactions with Experimental COVID-19 Therapies_LDIG.pdf
Intervenciones no farmacológicas para la contención, mitigación y supresión de la infección por COVID-19_Universidad de Antioquia.pdf
Listado de EECC para COVID-19 aprobados en España_EECC.pdf
Necesidad de encontrar farmacos frente a la enfermedad covid-19_ISCIII.pdf
Neuropsychiatric adverse events of chloroquine. A real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database_32321905.pdf
Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications (preprint).pdf
Non-steroidal anti-inflammatory drugs and covid-19_32220865.pdf
Nota informativa sobre el tratamiento con clozapina en el contexto de la crisis de la Covid-19_Generalitat de Catalunya.pdf
NZ health System Recommendations for entonox-in-labour-analgesia 7april2020_Ministry of Health_New Zealand.pdf
Observational Study of Hydroxychloroquine in Hospitalized Patients With Covid-19-32379955.pdf
Of chloroquine and COVID-19_32147496.pdf
Ongoing Clinical Trials for the Management of the COVID-19 Pandemic-32291112.pdf
Optimizing Medication Management during the COVID-19 Pandemic: Implementation Guide for Post-Acute and Long-Term Care_University of Maryland.pdf
Perspectives for the use of therapeutic Botulinum toxin as a multifaceted candidate drug to attenuate COVID-19-32352081.pdf
Perspectives on Monoclonal Antibody Therapy as Potential Therapeutic Intervention for Coronavirus disease-19 COVID-19 _32134278
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19) A review_32282022.pdf
Potential interventions for novel coronavirus in China Asystematic review_32052466.pdf
Preventing cytokine storm syndrome in COVID-19 using alpha-1 adrenergic receptor antagonists-32352407.v1.pdf
Protocolo Tratamiento según gravedad y evolución COVID19 Hospital UMostoles V4 08-04-20.pdf
Recomendaciones de tratamiento farmacológico en la infección por SARS-COV-2 en el ámbito extrahospitalario_SISCAT.pdf
Recomendaciones de tromboprofilaxis y tratamiento antitrombótico en pacientes con COVID-19_SETH.pdf
Recomendaciones para la obtención de plasma de donantes convalecientes de la enfermedad del Coronavirus SARS-CoV (COVID19)-Ministerio de Sanidad- Comité Científico Seguridad Transfusional_versión 15abril20.pdf
Regulators split on antimalarials COVID 19_32278373 .pdf
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro_32020029.pdf
Remdesivir como potencial terapia frente al COVID-19_informe v.2_BITN Osakidetza.pdf
Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence_32247927.pdf
Remdesivir in adults with severe COVID-19 a randomised, double-blind, placebo-controlled, multicentre trial_Lancet.pdf
Remdesivir in covid-19_32321732.pdf
Renin angiotensin system inhibitors improve the clinical outcomes of COVID 19 patients with hypertension_32228222.pdf
Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19_3235627.pdf
Review. Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)_32363212.pdf
Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection_32269021.pdf
Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine-32327397.pdf
Should ACE inhibitors and angiotensin II receptor blockers be stopped for COVID-19?(21-march-2020)_Ministry of Health Singapour.pdf
Should baricitinib be used for COVID-19?_Ministry of Health Singapour31-march-2020).pdf
Should convalescent plasma be used for COVID-19?.Ministry of Health Singapour.pdf
Should favipiravir be used for COVID-19?_Ministry of Health Singapour.pdf
Should ibuprofen be used for COVID-19?(21-march-2020) Ministry of Health Singapour.pdf
Should interleukin-6 (IL-6) inhibitors be used for COVID-19?_Ministry of Health Singapour(updated-15-april-2020).pdf
Should protease inhibitors be used for COVID-19?(updated-14-april-2020)_Ministry of Health Singapour.pdf
Should remdesivir be used for COVID-19?(updated-13-april-2020)_Ministry of Health Singapour.pdf
Some drugs being considered for treatment of COVIDー19_The Medical Letter on DrugsTherapeuctics.pdf
27 de abr.
Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19-initial assessment_32293807.pdf
Telemedicine in the Era of COVID-19_32220575.pdf
Temas de interés sobre: Medicamentos y COVID-19; Tratamientos del COVID-19; Flozinas_CADIME.pdf
The convalescent sera option for containing COVID-19_32167489.pdf
The Effect of Corticosteroid Treatment on Patients With Coronavirus Infection_A Systematic Review and Meta-Analysis-32283144.pdf
The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology A Systematic Review and Exploratory Meta-analysis_25030060.pdf
The Essential Facts of Wuhan Novel Coronavirus Outbreak in China and Epitope-based Vaccine Designing against COVID-19.pdf
The FDA-approved Drug Ivermectin inhibits the replication of SARS-1 CoV-2 in vitro_32251768.pdf
The possible of immunotherapy for COVID-19_A systematic review_32272396.pdf
The Urgency of Care During the Covid-19 Pandemic – Learning as We Go_32379956.pdf
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China_32222466.pdf
The versatile heparin in COVID-19-32239799.pdf
Tractament farmacologic de la infeccion per SARS COV2 Generalitat de Catalunya
Tratamiento farmacológico de la infección COVID-19 en adultos. Síntesis rápida.pdf
Tratamientos disponibles para el manejo de la infección respiratoria por SARS-CoV-2_AEMPS.pdf
Tratamientos potenciales para COVID-19 (Infección por SARS-CoV2)_AEP.pdf
Treatment Algorithm for Hospitalized Adults with Non–Severe COVID-19_YNHHS .pdf
Treatment and vaccines for severe acute respiratory syndrome_15766649.pdf
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma_32219428.pdf
Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmose_26198719.pdf
Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed_32278362
Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.pdf
Tweet de Nature Research (@nresearchnews)
Type and dose of heparin in COVID-19.pdf
Updated Approaches Against SARS-CoV-2_32205349.pdf
Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19)_32359771.pdf
Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic.pdf -32232419
Usefulness of Ivermectin in COVID-19 Illness.pdf
Virological and Clinical Cure in Covid-19 Patients Treated With Hydroxychloroquine A Systematic Review and Meta-Analysis-32297988.pdf
¿Cuál es la eficacia de la hidroxicloroquina en el tratamiento de la COVID-19_30 Marzo 2020_Cochrane Iberoamérica.pdf
[/kc_column_text][/kc_column][/kc_row]
